Treatment of Cryptococcus gattii Infection Using Voriconazole
| Autor: | Hideki Muramatsu, Shuntaro Hayashi, Hidefumi Sato, Sousuke Arakawa, Saori Tomita, Kohei Fujita, Makoto Nakao |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Voriconazole
medicine.medical_specialty biology business.industry General Medicine 030204 cardiovascular system & hematology biology.organism_classification Gastroenterology Flucytosine 03 medical and health sciences 0302 clinical medicine Cerebrospinal fluid Refractory Oral administration Cryptococcus gattii infection Internal medicine Internal Medicine Medicine 030211 gastroenterology & hepatology business Cryptococcus gattii Fluconazole medicine.drug |
| Zdroj: | Internal Medicine. 60:3635-3638 |
| ISSN: | 1349-7235 0918-2918 |
| Popis: | We previously reported a 39-year-old man who presented with pulmonary and cerebral Cryptococcus gattii (genotype VGIIa) infection and was successfully treated with liposomal amphotericin B and flucytosine induction therapy. Following induction therapy, oral fluconazole treatment was initiated as consolidation therapy. However, the patient complained of progressively worsening headache, presenting an elevated cerebrospinal fluid (CSF) cell count. The minimum inhibitory concentrations of the CSF isolate were 8 and 0.12 μg/mL for fluconazole and voriconazole, respectively. The oral administration of voriconazole for more than 18 months alleviated his symptoms. Voriconazole might be useful for controlling refractory cases of C. gattii infection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|